| PROBIODRUG AG Patent applications |
| Patent application number | Title | Published |
|---|
| 20120108449 | CRYSTAL STRUCTURE OF ISOGLUTAMINYL CYCLASE - A crystal comprising human isoglutaminyl cyclase having a characterised space group of P1211 and unit cell dimensions of +/−5% of a=126.51 Å, b=109.68 Å, c=159.53 Å, α=90.0°, β=104.9° and γ=90.0°. | 05-03-2012 |
| 20120070444 | IN VIVO SCREENING MODELS FOR TREATMENT OF isoQC-RELATED DISORDERS - A transgenic non-human animal for overexpressing isoQC, comprising cells containing a DNA transgene encoding human isoQC, characterized in that said human isoQC comprises the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 75% sequence identity to the amino acid sequence of SEQ ID NO: 1 or a fragment or derivative of the amino acid sequence of SEQ ID NO: 1. Additionally disclosed is a method of screening for biologically active agents that inhibit or promote isoQC. | 03-22-2012 |
| 20120064547 | DIAGNOSTIC ANTIBODY ASSAY - Novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided. | 03-15-2012 |
| 20120045815 | CRYSTAL STRUCTURE OF GLUTAMINYL CYCLASE - A novel crystal structures of human and murine glutaminyl cyclase (QC, EC 2.3.2.5), methods of preparing the crystals, as well as the use of said crystal structures for identifying inhibitors of human and murine glutaminyl cyclase. | 02-23-2012 |
| 20110262388 | NOVEL INHIBITORS - Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water. | 10-27-2011 |
| 20110224259 | NOVEL INHIBITORS - The invention relates to novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water. | 09-15-2011 |
| 20110224254 | NOVEL INHIBITORS - Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water. | 09-15-2011 |
| 20110212853 | NOVEL DIAGNOSTIC METHOD - A method of monitoring treatment of an inflammatory disease or an inflammatory associated disease with the use of the ratio of N-terminal pyroglutamate modified MCP-1 (MCP-1 N1pE):total concentration of MCP-1 within a biological sample as a biomarker, and a method for determining the proportion of N-terminal pyroglutamate modified MCP-1 in relation to the total concentration of MCP-1 in biological samples. Also disclosed are a diagnostic kit and a method for screening a glutaminyl cyclase (QC) inhibitor or measuring the effectiveness of a glutaminyl cyclase (QC) inhibitor. | 09-01-2011 |
| 20110166035 | NOVEL DIAGNOSTIC METHOD - Provided herein are methods, compositions, and kits related to the detection and diagnosis of a neurodegenerative disorder, such as Alzheimer's disease. Various aspects use the oligomeric state of fragments of amyloid β as a biomarker and further concerns a novel method to determine the oligomeric state of fragments of amyloid β in biological samples. | 07-07-2011 |
| 20110152341 | CLEAVAGE OF B-AMYLOID PRECURSOR PROTEIN - Methods and means for the identification of meprin-α and meprin-β as novel β-secretases and antagonists thereof for use in the treatment of amyloidosis. | 06-23-2011 |
| 20110092501 | NOVEL INHIBITORS - The invention relates to novel pyrrolidine derivatives of formula (I): | 04-21-2011 |
| 20110091910 | NOVEL ASSAY - A novel method for detection of Aβ peptides, in particular in plasma, and to the use of Aβ peptides for diagnosis of Alzheimer's disease. | 04-21-2011 |
| 20100299766 | MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE QPCTL-GENE - A knock-out non-human animal, in particular a mouse, carrying a QPCTL knock-out mutation. Additionally, respective cells and cell lines and methods and compositions for evaluating agents that affect QPCTL, for use in compositions for the treatment of QPCTL-related diseases are disclosed. | 11-25-2010 |
| 20100273835 | NOVEL COMPOUNDS - The invention provides compounds of general formula (I) | 10-28-2010 |
| 20100234397 | ENZYME INHIBITORS - There is disclosed herein methods for using compounds of formula (I), | 09-16-2010 |
| 20100159032 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS - The present invention provides a method for the treatment of neuronal disorders, in a mammal such as a human, which method comprises administering an effective, non-toxic and pharmaceutically acceptable amount of at least one QC-inhibitor, optionally in combination with at least one agent, selected from the group consisting of PEP-inhibitors, LiCl, inhibitors of DP IV/DP IV-like enzymes, NPY-receptor ligands, NPY agonists, NPY antagonists, ACE-inhibitors, PIMT enhancers, inhibitors of beta secretases, inhibitors of gamma secretases and inhibitors of neutral endopeptidase, to a mammal in need thereof. | 06-24-2010 |
| 20100125086 | USE OF ISOQC INHIBITORS - The present invention relates in general to an inhibitor of a glutaminyl peptide cyclotransferase-like protein (QPCTL), and the use thereof for the treatment and/or prevention of an inflammatory disease or disorder selected from the group consisting of (a) chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis; (b) other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis, Guillain-Barré syndrome, chronic inflammatory demyelinising polyradiculoneuropathy and multiple sclerosis; (c) neuroinflammation; and (d) neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, and Familial Danish Dementia, which may result from neuroinflammation. | 05-20-2010 |
| 20100119478 | ANTIBODIES DIRECTED AGAINST PYROGLUTAMATE MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1 N1pE) - Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE) are described. | 05-13-2010 |
| 20100119475 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of general formula (I): | 05-13-2010 |
| 20100099721 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - Inhibitors of prolyl endopeptidase of formula 1 | 04-22-2010 |
| 20100040575 | USE OF INHIBITORS OF GLUTAMINYL CYCLASE AND GLUTAMATE CYCLASE FOR TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES - Physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity. | 02-18-2010 |
| 20100028918 | GLUTAMINYL CYCLASE AS A DIAGNOSTIC/PROGNOSTIC INDICATOR FOR NEURODEGENERATIVE DISEASES - A method for predicting, diagnosing and prognosticating a neurodegenerative disease, such as Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and neurodegeneration in Down's syndrome (NDS) using glutaminyl cyclase (QC) as a diagnostic/prognostic indicator. The use of antibodies binding to QC and kits for performing said diagnostic method are also provided. | 02-04-2010 |
| 20100021478 | DIAGNOSTIC ANTIBODY ASSAY - The present invention pertains to novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided. | 01-28-2010 |
| 20100009337 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE - Novel glutaminyl-peptide cyclotransferase-like proteins (QPCTLs), which are isoenzymes of glutaminyl cyclase (QC, EC 2.3.2.5), and to isolated nucleic acids coding for these isoenzymes, all of which are useful for the discovery of new therapeutic agents, for measuring cyclase activity, and for determining the inhibitory activity of compounds against these glutaminyl cyclase isoenzymes. | 01-14-2010 |
| 20090269301 | Novel Inhibitors of Glutaminyl Cyclase - The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, | 10-29-2009 |
| 20090183267 | MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE QPCT-GENE - The present invention provides a knock-out non-human animal, in particular a mouse carrying a Qpct knock-out mutation. The present invention additionally provides the respective cells and cell lines and methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases. | 07-16-2009 |
| 20090149394 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES - The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of diseases that can be treated by modulation of QC-activity, e.g. diseases selected from the group consisting of duodenal cancer with or w/o | 06-11-2009 |
| 20090098052 | TRANSGENIC MICE - A transgenic non-human animal, in particular a transgenic mouse encoding Aβ peptide proteins, which have been implicated in Aβ peptide-related diseases. Cells and cell lines comprising transgenes encoding for Aβ peptide. Methods and compositions for evaluating agents that affect Aβ peptide, for use in compositions for the treatment of Aβ peptide-related diseases. | 04-16-2009 |
| 20090068699 | USE OF GLUTAMINYL CYCLASE INHIBITORS - An inhibitor of a glutaminyl peptide cyclotransferase, and use thereof for the treatment and/or prevention of a disease or disorder selected from the group consisting of inflammatory diseases selected from
| 03-12-2009 |
| 20090062203 | DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA AND DEPRESSION - A method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or of DP IV-like enzyme activity in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates by DP IV and DP IV-like enzymes. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1-36). As a consequence of the resulting enhanced stability of the endogenous NPY (1-36) caused by the inhibition of DP IV activity, NPY activity is prolonged thereby resulting among other things in functionally active NPY Y1 receptor activity thereby facilitating antidepressive, anxiolytic, analgesic, antihypertension and other neurological effects. | 03-05-2009 |
| 20090018087 | Novel Inhibitors of Glutaminyl Cyclase - The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia. | 01-15-2009 |
| 20080293618 | CYCLOPROPYL-FUSED PYRROLIDINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS - The present invention relates to DP IV-inhibitors of formula (1) | 11-27-2008 |
| 20080292582 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of formula (I), combinations and uses thereof for disease therapy, | 11-27-2008 |
| 20080286810 | Use of Inhibtors of Glutaminyl Cyclases for Treatment and Prevention of Disease - Novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity. | 11-20-2008 |
| 20080286231 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of formula (I), combinations and uses thereof for disease therapy, | 11-20-2008 |
| 20080267912 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of formula (I), combinations and uses thereof for disease therapy, | 10-30-2008 |
| 20080267911 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of formula (I), combinations and uses thereof for disease therapy, | 10-30-2008 |
| 20080262065 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASES - Compounds of formula (I), combinations and uses thereof for disease therapy, | 10-23-2008 |
| 20080262063 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of formula (I), combinations and uses thereof for disease therapy, | 10-23-2008 |
| 20080260688 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - Compounds of formula (I), combinations and uses thereof for disease therapy, | 10-23-2008 |
| 20080249083 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE - Novel glutaminyl-peptide cyclotransferase-like proteins (QPCTLs), which are isoenzymes of glutaminyl cyclase (QC, EC 2.3.2.5), and to isolated nucleic acids coding for these isoenzymes, all of which are useful for the discovery of new therapeutic agents, for measuring cyclase activity, and for determining the inhibitory activity of compounds against these glutaminyl cyclase isoenzymes. | 10-09-2008 |
| 20080234313 | NOVEL INHIBITORS - Compounds of formula (I), combinations and uses thereof for disease therapy, | 09-25-2008 |
| 20080221086 | Novel Inhibitors of Glutaminyl Cyclase - The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, | 09-11-2008 |
| 20080214620 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE - The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, | 09-04-2008 |
| 20080207715 | Novel Inhibitors of Glutaminyl Cyclase - The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, | 08-28-2008 |
| 20080200567 | IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS - A transgenic non-human animal, in particular a transgenic mouse, encoding Qpct proteins which have been implicated in Qpct-related diseases. Also disclosed are cells and cell lines comprising transgenes encoding for Qpct. Further disclosed are methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases. | 08-21-2008 |
